ATLANTA - Ruxolitinib reduces splenomegaly and other symptoms commonly associated with myelofibrosis, and the results are maintained for at least two years, according to results released at the 54th American Society of Hematology Annual Meeting. The findings are drawn from a median follow-up of 112 weeks in patients who were randomized in a 2:1 ratio to receive either oral ruxolitinib or best available therapy (BAT) as part of the Controlled Myelofibrosis Study with Oral JAK Inhibitor Treatment II (COMFORT-II) study...
via Health News from Medical News Today Read More Here..
No comments:
Post a Comment